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Background/aim: As the experience has increased regarding SARS-CoV-2 in time, treatment trends have changed since the beginning
of the pandemic. This study aimed to compare the outcomes of different treatment modalities for inpatients in a tertiary pandemic
hospital in Antalya, Turkey.
Materials and methods: Individuals aged 18 years and above who tested positive for SARS-CoV-2 in PCR with presenting COVIDrelated radiological findings, hospitalized for at least 3 days, and completed follow-up between March 15, 2020 and November 30, 2020
were included in the study. Patients’ data were reviewed retrospectively. Seven treatment groups based on the single or combined use
of hydroxychloroquine, oseltamivir, favipiravir, and remdesivir were formed and compared in terms of mortality, survival, length of
hospital stay, need for intensive care, and mechanical ventilation.
Results: A total of 321 patients were included in the study. The length of hospital stay, the need for intensive care, and mechanical
ventilation were lower in Group 1 (hydroxychloroquine) and Group 2 (hydroxychloroquine + oseltamivir) compared to the other
groups (p < 0.05). No significant difference was determined in survival between treatment groups. Analysis of prognostic factors
affecting overall survival revealed that the need for intensive care and mechanical ventilation increased mortality [11.1 times (p < 0.001)
and 6.48 times (p < 0.001), respectively].
Conclusion: No significant difference was determined between different treatment protocols in terms of their impact on survival. To
end the COVID-19 pandemic, there is an urgent need to develop highly efficient, rapid-acting, and orally available antiviral drugs.
Key words: COVID-19, treatment, favipiravir, remdesivir, hydroxychloroquine

1. Introduction
The SARS-CoV-2 pandemic continues to exist across the
world. Many agents currently used in treating COVID-19
are drugs such as hydroxychloroquine (HCQ), oseltamivir,
favipiravir (FAV), and remdesivir, which have been
effective in previous pandemics [1].
Since December 2019, when COVID-19 was identified
for the first time, treatment protocols in Turkey have
changed over time based on global and local guide
recommendations and changes in COVID-19 treatment
trends. In March 2020, the first case was determined in
Turkey, and treatment regimens according to the guidelines
of the Ministry of Health on COVID-19 began to be
applied in COVID-19 treatment1. Moreover, COVID-19
drugs are provided free of charge by the Ministry of Health.
At the beginning of the pandemic, only lopinavir/ritonavir

and HCQ were available for COVID-19 treatment in
Turkey. A few months later, FAV could be imported and
administered alone or combined with HCQ to patients at
a treatment dose of only 5 days. Towards the end of August
2020, FAV could be prescribed for 10 days.
Physicians from different countries used remdesivir,
donated by the manufacturer, in COVID-19 disease
(“compassionate use”) [2]. Remdesivir, which was
available in limited numbers in our hospital, was obtained
by applying to the Republic of Turkey, Ministry of Health
Drugs and Medical Devices Agency and could only be
used in a few patients who were unresponsive to initial
treatment and had a severe clinical condition.
Initially, steroids were not recommended for the
treatment of COVID-19. However, they began to be used
after the inclusion of “6 mg/day of dexamethasone, 40 mg/

Republic of Turkey Ministry of Health (2020). COVID-19 (SARS-CoV-2 Infection) Guide, 11.03.2020 [online]. Website www.hsgm.saglik.gov.tr
[accessed April 3, 2021].
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day of prednisolone or 32 mg/day of methylprednisolone
can be prescribed for patients who required oxygen” in
the COVID-19 treatment guidelines of the Ministry of
Health on August 2, 20202. Tocilizumab is in the “off-label”
treatment category for COVID-19 in Turkey and is used
in patients with cytokine storms upon application to the
health authority and the subsequent approval. High-cost
“cytokine adsorption” (via cytokine adsorber, CytoSorb ®)
can only be administered to patients who are admitted to
intensive care, do not respond to standard treatment and
steroids, and have a severe disease and cytokine storm.
This study aimed to retrospectively evaluate the
effects of four primary drugs (HCQ, oseltamivir,
FAV, and remdesivir) and seven different treatment
protocols consisting of a combination of these drugs on
hospitalization, need for intensive care and mechanical
ventilation, and survival in patients who met the inclusion
criteria in our tertiary training and research hospital
assigned as a pandemic hospital since the first case was
identified in Turkey.
2. Materials and methods
The study retrospectively included 321 patients aged 18
and above who tested positive for SARS-CoV-2 in PCR
test with COVID-related pneumonia in the computerized
tomography of the chest and were hospitalized for at least
3 days with a completed follow-up between March 15,
2020 and November 30, 2020. Even if their tomography
findings were compatible with COVID-19 pneumonia,
cases not confirmed by a PCR test, pregnant women, and
patients under 18 years of age were excluded.
Seven main treatment groups were defined. Since
HCQ + azithromycin and lopinavir/ritonavir were used
for a short period in very few patients, those who received
these treatments were not included in the study. The main
treatment groups in this study were as follows: Group 1 =
HCQ for 5 days, Group 2 = HCQ + oseltamivir for 5 days,
Group 3 = FAV for 5 days, Group 4 = FAV for 5 days after
HCQ ± oseltamivir for 5 days, Group 5 = FAV for 10 days,
Group 6 = FAV + HCQ for at least 5 days, Group 7 =
Remdesivir treatment after FAV for at least 5 days.
In addition, whether the treatments of immune plasma
(one dose of 200 mL), cytokine adsorption (CytoSorb®,
for 3 days), low molecular weight heparin (LMWH,
enoxaparin sodium 4000 or 6000 IU subcutaneously daily),
vitamin C (2000 mg intravenously daily), and tocilizumab
(400 mg or 800 mg/total dose) were administered in each
of these groups was recorded. The main treatment groups
were also compared regarding patients’ length of hospital
stay, need for intensive care and mechanical ventilation,

and mortality.
The severity of pneumonia was classified at the
initiation of treatment based on the low-dose unenhanced
chest tomography results3.
Unilateral or bilateral, peripheral or adjacent to fissure,
small, partially round ground-glass opacities, mainly in
the lower lobes, were staged as “mild”; bilateral, multifocal,
more extended involvements in tomography as less than
50% of the parenchyma, up to the upper lobes of the
lung, were staged as “moderate”; widespread involvement
over 50% of the bilateral lung parenchyma, consolidation
accompanying ground-glass opacities, or tomography
findings of air bronchogram or crazy-paving were staged
as “severe” pneumonia [3].
Standard treatment doses in each patient were as
follows: 2 × 200 mg of HCQ (orally) for 5 days, 2 × 75
mg of oseltamivir for 5 days, 2 × 1600 mg of FAV on day
zero and 2 × 600 mg on other 4 or 9 days, and 200 mg of
remdesivir (intravenously) on the first day and 100 mg/
day for 4 days.
2.1. Statistical analysis
The data were analyzed using IBM SPSS Statistics 18, 2010
software. The Kolmogorov–Smirnov test determined the
compliance of continuous variables to normal distribution.
The categorical variables were presented in frequency and
percentage, and continuous variables in mean, standard
deviation, median, minimum, and maximum values.
The chi-square significance test analyzed the categorical
variables and made a post hoc Bonferroni correction. Oneway ANOVA determined the mean value comparisons
of more than two groups, post hoc LSD tests were used
when parametric test assumptions were met, and the
Kruskal–Wallis and post hoc pairwise comparison tests
in other cases. The survival rates were estimated using the
Kaplan–Meier method, and a log-rank test was performed
to examine whether there was a difference between the
variable levels in terms of survival probabilities. Next,
Cox regression analysis determined the factors affecting
survival. Possible factors identified by univariate analyses
were analyzed with a multiple logistic regression model.
The statistical significance level was considered to be 0.05
in the study.
3. Results
3.1. General demographic and clinical characteristics
Three hundred twenty-one patients who met the inclusion
criteria were included in the study. One hundred eightynine patients (58.9%) were male, and the mean age was
56.11 ± 14.67 years. Of the 274 patients with an accessible

Republic of Turkey Ministry of Health (2020). COVID-19 (SARS-CoV-2 Infection) Guide, 02.08.2020 [online]. Website https://toraks.org.tr/site/sf/
nmf/2020/08/16c01709f0a799d5529e2f29648de7b4cc7dff09378 [accessed April 3, 2021].
2

Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 Infection) guide, 9.10. 2020. [online]. Website https://covid19.saglik.gov.tr/
Eklenti/39061/0/covid19rehberieriskinhastatedavisipdf.pdf [accessed April 3, 2021].
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smoking history, 87 (31.8%) were smokers. The mean time
from the onset of symptoms to the initiation of the main
treatment was 3.57 ± 3.41 days. One hundred two patients
(31.8%) had mild COVID-19 pneumonia, whereas 116
(36.1%) had severe COVID-19 pneumonia on admission.
The mean length of hospital stay of the patients was 12 ±
10.31 days, and the mean length of stay in intensive care
was 15.38 ± 11.86 days. Ninety-eight patients (30.5%)
required intensive care and 67 (20.9%) mechanical
ventilation during follow-up. The main treatment groups
and the number of patients in each group were as follows:
Group 1: HCQ for 5 days (n = 44) (13.7%)
Group 2: HCQ+ oseltamivir for 5 days (n = 31) (9.7%)
Group 3: FAV for 5 days (n = 73) (22.7%)
Group 4: FAV for 5 days after HCQ ± oseltamivir (n =
33) (10.3%)
Group 5: FAV for 10 days (n = 82) (25.5%)
Group 6: FAV+HCQ for at least 5 days (n = 41) (12.8%)
Group 7: Remdesivir after FAV for at least 5 days (n =
17) (5.3%)
Other than the main treatments, steroid treatment was
administered to 124 patients (38.6%) due to low oxygen
saturation during the follow-up. Methylprednisolone was
the most common steroid type and was administered to
68.5% of patients (85/124). The steroids were added to the
treatment regime with an average of 6.19 ± 3.53 days after
symptom onset. Fifty-eight (18.1%) patients underwent
immune plasma therapy, and the mean value of the time
from the symptom onset to the administration of immune
plasma was 8.69 ± 4.62 days. LMWH was administered in
266 patients (82.9%) after an average of 4.91 ± 3.60 days
from the onset of symptoms. Two hundred forty-four
(76%) patients were applied intravenous vitamin C of 2
g/day during their stay at the hospital. Tocilizumab was
applied to 15 patients (4.7%) diagnosed with cytokine
storm associated with COVID-19 and cytokine adsorption
to 22 patients (6.9%), and both of them to 5 patients. The
overall mortality rate due to all causes was 20.6% (n =
66) with the following reasons: cardiac arrest (n = 35),
sepsis (n = 15 (bacterial sepsis = 13 and fungal sepsis =
2)), multiorgan failure (n = 10) and respiratory arrest (n
= 6). The mortality rate within 14 days after diagnosis
was 7.5% (n = 24). The general demographic and clinical
characteristics of the patients are presented in Table 1.
3.2. Presenting symptoms and comorbidities
The patients were most frequently presented with
symptoms of dry cough (n = 197, 61.4%), fever (n = 180,
56.1%), and fatigue (n = 155, 48.4%). There was at least one
comorbidity in 52% of the patients (n = 167). The survival
rate was significantly lower in those with comorbidity than
those without (p < 0.001). The most common comorbidity
was hypertension (n = 104, 32.4%) and patients with
hypertension had a lower survival rate than those with

other comorbidities (p < 0.001). The second most common
comorbidity was diabetes mellitus (n = 91, 28.3%).
3.3. Laboratory data for presenting values
Table 1 indicates the general laboratory data on admission
and the highest Interleukin-6 (IL-6) and D-Dimer levels
during the follow-up.
3.4. Demographic and clinical characteristics by main
treatment groups
The mean age of the patients in Group 5 was higher than
all other groups (p < 0.05). The mean age of the patients
in Groups 1 and 2 was lower than those in Groups 3, 5,
and 6 (p < 0.05). Group 1 had the lowest mean age (47.20
± 13.58 years). The mean age values of the groups were
similar except for Group 1, 2, and 5. The smoking rate in
Group 1 was significantly lower than Group 7 (14.3% and
57.1%, respectively) (p < 0.05). There was no significant
difference in smoking rates in the other groups. There was
no significant difference between the seven main treatment
groups regarding the time from the onset of symptoms
to the initiation of treatment. Pneumonia severity at the
beginning of treatment was similar in Groups 1 and 2, and
these groups had the highest rate of mild pneumonia (p <
0.05). Groups 5, 6, and 7 had a similar and highest rate of
severe pneumonia, and Groups 1 and 2 had the lowest rate
(p < 0.05). The length of hospitalization in the inpatient
clinic was shorter in Group 2 than in Groups 4 and 5 (p
< 0.05). There was no significant difference between the
other groups in this regard. The total length of hospital
stay was shorter in Groups 1 and 2 (p < 0.05) and higher
in Group 7 than the others (p < 0.05). The admission
rate to intensive care was similar in Groups 1 and 2 and
significantly lower than the others (p < 0.05). It was similar
in Groups 6 and 7, as the highest in Group 7 (p < 0.05).
Mechanical ventilation rate was similar in Groups 1 and 2
and significantly lower than the others (p < 0.05). Groups 3,
4, 5, and 6 had similar results, and Group 7 had the highest
rate (p < 0.05). Demographic and clinical characteristics
by the treatment groups are summarized in Table 2.
3.5. Laboratory data for the presenting values in main
treatment groups
The mean value of fasting blood glucose in Group 1 was
lower than Groups 3, 5, 6, and 7. The difference was
statistically significant (p < 0.05). At the initial admission,
C-reactive protein (CRP), albumin level, neutrophil
lymphocyte ratio (N/L), lactate dehydrogenase (LDH)
level, ferritin level, and peak D-dimer levels were similar
in Groups 1 and 2 and lower than the other groups, which
was statistically significant (p < 0.05). Lymphocyte count
was significantly lower in Group 7 than in Groups 1 and 2
(p < 0.05). Laboratory data for the presenting values of the
seven treatment groups are presented in Table 3.
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Table 1. General demographic-clinical characteristics and general laboratory data (n = 321).
Age (years)

56.11 ± 14.67 (mean ± SD) 19–91 (56) min-max (med)

Sex (male)

189 (n)

58.9 (%)

Smoker

87/274 (n)

31.8 (%)

Time from the symptom onset to the initiation of main treatment (days)

3.57 ± 3.41 (mean ± SD)

0–24 (3) min-max (med)

Intensive care stay (days)

15.38 ± 11.86 (mean ± SD) 1–82 (12) min–max (med)

Inpatient clinic stay (days)

6.01 ± 5.84 (mean ± SD)

Total length of hospital stay (days)

12.00 ± 10.31 (mean ± SD) 3–83 (9) min-max (med)

Need for intensive care

98 (n)

30.5 (%)

Mechanical ventilation

67 (n)

20.9 (%)

Mild

102 (n)

31.8 (%)

Moderate

103 (n)

32.1 (%)

Severe

116 (n)

36.1 (%)

Patients receiving steroids

124 (n)

38.6 (%)

Methylprednisolone

85 (n)

68.5 (%)

Dexamethasone

39 (n)

31.5 (%)

Time from symptom onset to the administration of steroids (days)

6.19 ± 3.53 (mean ± SD)

0–15 (6) min-max (med)

Patients receiving immune plasma

58 (n)

18.1 (%)

0–29 (4) min-max (med)

Pneumonia severity at the beginning of the main treatment

Steroid type (n: 124)

Time from symptom onset to the administration of immune plasma (days) 8.69 ± 4.62 (mean ± SD)

0–23 (8) min-max (med)

Patients receiving LMWH

266 (n)

82.9 (%)

Time from the onset of symptoms to the administration of LMWH (days)

4.91 ± 3.60 (mean ± SD)

0–21 (4) min-max (med)

Patients receiving vitamin C

244 (n)

76.0 (%)

Tocilizumab

15 (n)

4.7 (%)

400 mg

10 (n)

66.7 (%)

800 mg

5 (n)

33.3 (%)

Cytokine adsorption

22 (n)

6.9 (%)

Overall mortality

66 (n)

20.6 (%)

14-day mortality

24 (n)

7.5 (%)

Tocilizumab dose

Mortality

28-day mortality

55 (n)

17.1 (%)

Laboratory test variable (n: 321)

Mean ± SD

Median

Min-max

Glucose (mg/dL)

145.23 ± 64.21

123

68–418

AST (U/L)

41.39 ± 44.90

29

8–408

ALT (U/L)

37.43 ± 32.22

Creatinine (mg/dL)

1.04 ± 0.69

Albumin (g/dL)

3.72 ± 0.51

Leukocyte (103/mm3)

6892.97 ± 3147.48

Lymphocyte (10 /mm )

1237.16 ± 670.93

N/L

5.76 ± 6.54

3

3

Platelet (10 /mm )

209.97 ± 775.5

Troponin (ng/L)

12.03 ± 22.16

3
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Table 1. (Continued).
Myoglobin (ng/mL)

86.15 ± 195.52

LDH (U/L)

317.22 ± 137.14

Ferritin (µg/L)

404.18 ± 505.9

CRP (mg/dL)

82.14 ± 85.28

Procalcitonin (ng/mL)

0.98 ± 7.23

IL-6 (pg/mL) (on admission)

106.28 ± 202.48

IL-6 (pg/mL) (peak)

297.67 ± 826.66

D-dimer (µg/L) (on admission)

717.74 ± 3719.13

D-dimer (µg/L) (peak)

1817.3 ± 5886.06

LMWH: Low-molecular-weight heparin, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, N/L: Neutrophil-tolymphocyte ratio, LDH: Lactate dehydrogenase, CRP: C-reactive protein, IL-6: Interleukin 6

3.6. Comorbidities by the groups
The difference between Groups 1 and 5 in terms of
comorbidities was statistically significant, and the rate
of comorbidities was significantly lower in Group 1 (p
< 0.05). There was no significant difference between
the other groups in terms of comorbidities. In Group 1,
diabetes mellitus (DM) was significantly less common
than Groups 3 and 5, and Hypertension (HT) was less
common than Groups 5 and 6 (p ˂ 0.05). Comorbidities
by treatment groups are shown in Table 4.
3.7. Mortality rates by treatment groups
Overall mortality and 28-day mortality were lower in
Groups 1 and 2 than the others (p ˂ 0.05). Mortality rates
by the treatment groups are summarized in Table 5.
3.8. Treatments and practices other than main treatment
by the groups
Steroid use was higher in Groups 5, 6, and 7 than others (p
< 0.05). It was found that steroids were given to 69.5% of
Group 5 (n = 57), 46.3% of Group 6 (n = 19), and 76.5%
of Group 7 (n = 13). Immune plasma was administered to
82.4% of Group 7 at a higher rate than the other groups (p
< 0.05). The remaining groups had no significant difference
in the use of immune plasma. Among the main treatment
groups, the LMWH was used least in Group 2 (6.5%), and
the difference was statistically significant (p < 0.05). The
use of LMWH was 72.7%–100% in the remaining groups,
with no significant difference between groups. Vitamin C
use was higher in Groups 4, 5, and 7 than in other groups,
and the difference was statistically significant (p < 0.05).
Tocilizumab was used in only 4.7% (n = 15) of the patients,
and 6 of them were in Group 6 (14.8%), and three were in
Group 7 (17.6%). The cytokine adsorption rate was higher
in Group 7 than the others (p < 0.05). We found that 8 of
the 22 patients who underwent cytokine adsorption were
in Group 7, and 47.1% of Group 7 had cytokine adsorption.
Treatments and practices other than the main treatment
by the groups are presented in Table 6.

3.9. Results of survival analysis
The mean age of patients who died was significantly
higher than those who survived (67.77 ± 10.39 vs 53.09
± 14.11 years, p < 0.001). The survival rate was examined
based on the severity of pneumonia at the beginning of
antiviral therapy and found as 94.1% in patients with mild
pneumonia and 65% in those with severe pneumonia, and
the difference was significant (p < 0.001). The pneumonia
was analyzed in two groups as “mild + moderate” and
“severe” based on its severity. The survival rate was 87.3%
in “mild + moderate” pneumonia and 65.5% in severe
pneumonia (p < 0.001). The survival rate was lower in those
with comorbidity than those without (71.3% vs. 88.35) (p <
0.001). The survival rate in patients who required intensive
care during follow-up was significantly lower than those
who did not (34.7% and 99.1%, respectively) (p < 0.001).
Among them, the survival rate was much lower in patients
who required mechanical ventilation compared to those
who did not (13.4% and 96.9%, respectively) (p < 0.001).
It was noteworthy that the survival was higher in patients
who did not receive immune plasma than in those who did
(89% vs. 36.2%) (p < 0.001). As expected, survival was lower
in the group of patients in severe condition who underwent
tocilizumab and cytokine adsorption (p < 0.001 and p <
0.001, respectively). The survival rate was higher in Group
1 (HCQ for 5 days) and Group 2 (HCQ + oseltamivir for
5 days) compared to the others, and the difference was
significant (p < 0.001). Survival rates by the demographic
and clinical characteristics are shown in Table 7.
The survival analysis on the general clinical
characteristics of the patients through the Kaplan–Meier
and log-rank tests revealed that sex, smoking, presence
of any comorbidity, and severity of pneumonia at the
beginning of treatment did not lead to any statistically
significant difference in survival. We found that survival
was significantly lower in those admitted to intensive
care and those mechanically ventilated, and the difference
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Table 2. Demographic and clinical characteristics by the treatment groups.
Group 3
(n: 73)

Group 4
(n: 33)

Group 5
(n: 82)

Group 6
(n: 41)

Group 7
(n: 17)

Overall
(n: 321)

<0.05a

56.11 ± 14.67

Agea (years) (mean ± SD)

47.20 ± 13.58 48.97 ± 14.80 58.42 ± 13.73 54.39 ± 13.61 62.99 ± 14.25 56.41 ± 12.21 51.59 ± 12.98

Sex male n(%)

21 (47.7)

11 (35.5)

48 (65.8)

24 (72.7)

47 (57.3)

27 (65.9)

11 (64.7)

>0.05

189 (58.9)

Smokerb (n: 274) n (%)

5 (14.3)

7 (24.1)

15 (25.4)

8 (25.8)

31 (40.3)

13 (44.8)

8 (57.1)

<0.05b

87 (31.8)

Time from symptom onset to
treatment (days) mean (min-max)

2 (0–14)

4 (0–24)

2 (0–10)

3 (0–11)

3 (0–15)

4 (0–12)

3 (0–7)

=0.651

3 (0–24)

Stay in ICU* (days) mean (min-max)

–

–

12 (1–82)

17 (7–35)

9.5 (2–28)

14 (6–65)

16 (6–40)

>0.05

12 (1–82)

Inpatient clinic stay (days) mean
(min-max)

5 (0–18)

5 (0–16)

5 (0–21)

8 (0–33)

7 (0–30)

7 (0–20)

7 (0–17)

<0.05c

6 (0–33)

Total stayd (days) mean (min-max)

5 (3–18)

5 (3–16)

8 (3–83)

11 (3–53)

10 (3–50)

13 (4–67)

20 (7–45)

<0.05d

9 (3–83)

Need for ICU n (%)

1 (2.3)

0 (0.0)

24 (32.9)

10 (30.3)

30 (36.6)

19 (46.3)

14 (82.4)

>0.05

98 (30.5)

Mechanical ventilation n(%)

1 (2.3)

0 (0.0)

18 (24.7)

7 (21.2)

19 (23.2)

11 (26.8)

11 (64.7)

>0.05

67 (20.9)

Pneumonia severity (mild) n (%)

26 (59.1)

18 (58.1)

26 (35.6)

9 (27.3)

14 (17.1)

9 (22.0)

0 (0.0)

>0.05

102 (31.8)

Pneumonia severity (moderate) n (%)

12 (27.3)

10 (32.3)

25 (34.2)

13 (39.4)

23 (28.0)

12 (29.3)

8 (47.1)

>0.05

103 (32.1)

Pneumonia severity (severe)

6 (13.6)

3 (9.7)

22 (30.1)

11 (33.3)

45 (54.9)

20 (48.8)

9 (52.9)

>0.05

116 (36.1)

The mean age of the patients in Group 5 was significantly higher than all other groups. The mean age of the patients in Group 1 is significantly lower than those in Groups 3, 4, 5,
and 6. The mean age of the patients in Group 2 is significantly lower than those in Groups 3, 5, and 6 (p < 0.05, one-way ANOVA, post hoc LSD test was used for statistical analysis).
b
Smoking rate in Group 1 was significantly lower than in Group 7 (p < 0.05, chi-square, post hoc Bonferroni test was used for statistical analysis).
c
The length of stay in inpatient clinic was significantly shorter in Group 2 than in Groups 4 and 5 (p < 0.05, the Kruskal–Wallis and post hoc pairwise comparisons test were used
for statistical analysis).
d
Total length of stay was significantly shorter in Groups 1 and 2 compared to other Groups and longer in Group 7 (p < 0.05, the Kruskal–Wallis and post hoc pairwise comparisons
test were used for statistical analysis).
The variables are presented as mean ± SD or median (min-max) and n (%).
*: Intensive care unit
a
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Group1
(n: 44)

c

Group 2
(n: 31)

p
value

Variable

Table 3. Laboratory data for the presenting values by the main treatment groups.
Overall
(n: 321)

126.5 (88–300) 129 (83–224)

<0.05

123 (68–418)

23 (11–111)

35.5 (9–408)

29 (15–64)

<0.05

29 (8–408)

29.5 (8–110)

30 (8–242)

40 (16–65)

<0.05

29 (4–315)

0.9 (0–5)

1 (0–8)

1 (1–3)

0.9 (0–2)

<0.05

0.9 (0–8)

3.8 (2.8–4.6)

3.6 (2.1–4.4)

3.6 (2.1–4.6)

3.6 (2.6–4.1)

<0.05

3.7 (2.1–5)

5600
(3300–19400)

6000
(3800–16100)

6700
(770–17100)

7100
(2000–16100)

7000
(1200–17300)

<0.05

6100
(770–19400)

1400
(200–3800)

1200
(80–4500)

1000
(100–2200)

1100
(200–5400)

1000
(500–3000)

800
(300–1800)

<0.05

1200
(80–5400)

2 (1–8)

3.7 (1–50)

3.9 (2–57)

5 (1–32)

5.2 (1–23)

9 (2–37)

<0.05

3.8 (1–57)

196 (28–385)

202 (74–363)

197 (79–661)

200 (82–379)

199 (85–517)

=0.895

202 (21–661)

3 (3–21)

6.5 (3–165)

3 (3–104)

5 (2–176)

6.5 (3–34)

3 (3–150)

<0.05

4 (2–176)

25 (21–80)

57 (21–690)

38 (21–734)
272.5 (156–
208 (119–476) 229.5 (13–402) 300 (136–975)
563)
95
90
223.5
256
(3–1788)
(4–770)
(5–1967)
(26–2443)

50 (16–2621)

45 (21–445)

45 (20–120)

<0.05

38.5 (16–2621)

CRP (mg/dL)

10 (1–300)

13.5 (0–180)

55 (1–473)

Procalcitonin (ng/mL)

0.06 (0–26)

0.06 (0–0)

0.08 (0–30)

IL-6 (presenting) (pg/mL)

12 (2–1408)

6 (2–41)

IL-6 (peak) (pg/mL)

22
(2–5000)

D-dimer (presenting) (µg/L)
D-dimer (peak) (µg/L)

Group 1
(n: 44)

Group 2
(n: 31)

Group 3
(n: 73)

Group 4
(n: 33)

Group 5
(n: 82)

Group 6
(n: 41)

Fasting blood glucose (mg/dL)

98 (76–245)

114 (81–221)

128 (68–394)

109 (85–238)

136 (81–418)

AST (U/L)

23 (14–67)

25 (15–115)

31 (8–391)

30 (13–85)

ALT (U/L)

24 (6–61)

19.5 (7–161)

32.5 (4–315)

29 (10–110)

Creatinine (mg/dL)

0.8 (0–4)

0.7 (1–1)

0.9 (0–5)

Albumin (g/dL)

4.3 (2.3–5.0)

4.2 (3.3–5.0)

3.6 (2.4–4.6)

Leukocyte (103/mm3)

5400
(2700–11600)

5200
(2800–12400)

Lymphocyte (103/mm3)

1350
(200–3000)

N/L

2.3 (1–13)

Platelet (103/mm3)

206.5 (21–405) 214 (90–323)

Troponin (ng/L)

3 (3–18)

Myoglobin (ng/mL)

22 (21–522)

LDH (U/L)
Ferritin (µg/L)

Group 7
(n: 17)

311.5 (90–715) 334 (153–758) 340 (215–747) <0.05

284 (13–975)

303
(29–4279)

305.5
(21–1941)

454.5
(86–2525)

<0.05

244
(3–4279)

40 (1–208)

91 (6–370)

88 (2–229)

87 (23–318)

<0.05

54 (0–473)

0.1 (0–3)

0.08 (0–23)

0.1 (0–1)

0.6 (0–106)

<0.05

0.09 (0–106)

89.5 (6–638)

45.5 (6–295)

35 (2–934)

67 (3–1309)

61 (2–508)

<0.05

42 (2–1408)

6.3
(2–41)

132.15
(0–638)

69
(17–5000)

60
(2–1128)

113
(3–5000)

135.5
(28–3054)

<0.05

83.5
(0–5000)

183
(10–5207)

118
(36–794)

293
(70–62484)

198
(38–5428)

262
(48–5152)

272
(106–2978)

287
(105–16676)

<0.05

238.5
(10–62484)

204
(19–10900)

148
(36–1405)

515
(70–62484)

408
(43–6455)

497
(48–10540)

511
(156–11791)

1350
(150–55001)

<0.05

370
(19–62484)

2841

- The variables are presented as mean ± SD or median (min-max) and n (%).
- AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, N/L: Neutrophil-to-lymphocyte ratio, LDH: Lactate dehydrogenase, CRP: C-reactive protein, IL-6: Interleukin 6
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p
value

Variable
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Table 4. Comorbidities by treatment groups.
Variable
n (%)

Group1
(n: 44)

Group 2
(n: 31)

Group 6
(n: 41)

Group 4
(n: 33)

Group 5
(n: 82)

Group 6
(n: 41)

Group 7
(n: 17)

Overall
(n: 321)

Comorbidities a

13 (29.5)

14 (45.2)

41 (56.2)

13 (39.4)

53 (64.6)

25 (61.0)

8 (47.1)

167 (52.0)

DM

4 (9.1)

9 (29.0)

30 (41.1)

5 (15.2)

30 (36.6)

11 (26.8)

2 (11.8)

91 (28.3)

HT c

6 (13.6)

7 (22.6)

26 (35.6)

8 (24.2)

35 (42.7)

18 (43.9)

4 (23.5)

104 (32.4)

CAD, HF, HL

4 (9.1)

4 (12.9)

12 (16.4)

1 (3.0)

16 (19.5)

5 (12.2)

1 (5.9)

43 (13.4)

Obesity

1 (2.3)

0 (0.0)

5 (6.8)

3 (9.1)

12 (14.6)

5 (12.2)

4 (23.5)

30 (9.3)

Other

4 (9.1)

4 (12.9)

21 (28.8)

8 (24.2)

20 (24.4)

13 (31.7)

4 (23.5)

74 (23.1)

b

There was a significant difference between Groups 1 and 5 in terms of comorbid disease (p < 0.05, chi-square, post hoc Bonferroni test
was used for statistical analysis).
b
DM was less in Group 1 than in Groups 3 and 5 (p < 0.05, chi-square, post hoc Bonferroni test was used for statistical analysis).
c
HT was less in Group 1 than in Groups 5 and 6 (p < 0.05, chi-square, post hoc Bonferroni test was used for statistical analysis).
-The variables are presented as n (%).
-Abbreviations: DM: Diabetes mellitus, HT: Hypertension, CAD: Coronary artery disease, HF: heart failure, HL: Hyperlipidemia
a

Table 5. Main treatment groups and mortality.
Variable
n (%)

Group 1
(n: 44)

Group 2
(n: 31)

Group 3
(n: 73)

Group 4
(n: 33)

Group 5
(n: 82)

Group 6
(n: 41)

Group 7
(n: 17)

Overall
(n: 321)

p value

Overall mortality

1 (2.3)

0 (0.0)

20 (27.4)

6 (18.2)

21 (25.6)

11 (26.8)

7 (41.2)

66 (20.6)

0.05

28-day mortality

1 (2.3)

0 (0.0)

18 (24.7)

4 (12.1)

20 (24.4)

6 (14.6)

6 (35.3)

55 (17.1)

0.05

The variables are presented as n (%).

was statistically significant (p < 0.001 and p < 0.001,
respectively). In univariate Cox regression analyses
performed to determine the prognostic factors affecting
overall survival, we found that intensive care unit (ICU)
admission increased mortality by 11.1 times (p < 0.001), and
mechanical ventilation increased mortality by 6.48 times (p
< 0.001). The variables found significant were included in
the multivariate Cox regression analysis. Multivariate Cox
regression analysis showed that mechanical ventilation
increased mortality by 3.987 times (p < 0.001).
In the multivariate Cox regression analysis, there was no
significant difference between the main treatment groups’
impact on survival. Survival analyses by the treatment
groups and main clinical characteristics are shown in Table
8. Cumulative survival by the main treatment groups is
presented in Figure.
Possible factors identified by univariate analyses
were analyzed with a multiple logistic regression model.
Logistic regression analysis of risk factors for mortality
is shown in Table 9. Accordingly, every 1 year of increase
in age increased mortality 1.074 times (p = 0.005); ICU
hospitalization increased mortality 14.7 times (p = 0.003),
and the need for mechanical ventilation increased mortality
29.1 times (p < 0.001).

2842

4. Discussion
At the beginning of the COVID-19 pandemic, there
were problems in drug supply in Turkey and the world.
In the first month of the pandemic in Turkey, only HCQ
could be used in treating hospitalized patients. FAV was
included in treatment later on. Remdesivir was available
in a limited number and could not be used later due to
the depletion of donated medicine stock. Tocilizumab,
on the other hand, is used under the control and
permission of the health authority. Therefore, treatment
protocols had to be organized depending on the drugs
we had access to at that moment.
In March 2020, the first COVID-19 case was
identified in Turkey. Since then, the scope and duration
of the treatments have changed due to the changes
in treatment guidelines and the drugs available. We
performed this study to clarify which one of the main
treatments was superior in survival and found no
significant differences between the groups regarding the
impact on survival, according to the multivariate Cox
regression analysis.
To interpret the results better, we examined the
variables such as the number of patients in the groups,
their clinical-demographic characteristics, the initiation

Table 6. Treatments and practices other than main treatment by the groups.
Variable

G1
(n: 44)

G2
G3
(n: 31) (n: 73)

G4
(n: 33)

G5
(n: 82)

G6
(n: 41)

G7
(n: 17)

p
value

Steroid a

0 (0.0)

0 (0.0) 29 (39.7)

6 (18.2)

57 (69.5)

19 (46.3)

13 (76.5)

<0.05a 124 (38.6)

Methylprednisolone (n: 124)

-

-

27 (93.1)

6 (100.0) 27 (47.4)

15 (78.9)

10 (76.9)

>0.05 85 (26.5)

Dexamethasone (n: 124) b

-

-

2 (6.9)

0 (0.0)

4 (21.1)

3 (23.1)

<0.05b 39 (31.5)

Time from symptom onset to the administration of steroids (days)

-

-

5(0–11)

9.5 (3–10) 6(0–15)

7 (0–15)

7 (1–10)

>0.05 6 (0–15)

Immune plasma c

0 (0.0)

0 (0.0) 12 (16.4)

5 (15.2)

9 (22.0)

14 (82.4)

<0.05c 58 (18.1)

(1–18) 10.5 (0–13) 6 (2–14)

>0.05 8 (0–23)

LMWH

-

9.5 (5–16) 11 (7–23) 8

39 (88.6) 2 (6.5) 66 (90.4)

24 (72.7) 81 (98.8)

Time from symptom onset to the administration of LMWH (days)

2 (0–14)

7 (5–9) 3 (0–11)

Tocilizumab f (n: 320)

0 (0.0)

Vitamin C

d
e

g

Cytokine adsorption h

37 (90.2)

17 (10.0)

<0.05d 266 (82.9)

8 (3–21)

5 (0–15) 5 (0–11)

4 (1–10)

<0.05e 4 (0–21)

0 (0.0) 4 (5.5)

1 (3.0)

1 (1.2)

6 (14.8)

3 (17.6)

<0.05f 15 (4.7)

22(50.0)

9 (29.0) 59 (80.8)

29 (87.9) 80 (97.6)

29 (70.7)

16 (94.1)

<0.05g 244(76.0)

1 (2.3)

0 (0.0) 1 (1.4)

4 (12.1)

4 (9.8)

8 (47.1)

<0.05h 22 (6.9)

Steroid usage was higher in Groups 5, 6, 7 than others (p < 0.05).
Groups 3 and 5 were different from each other in terms of dexamethasone usage (p < 0.05).
c
Group 7 differed from the others in the use of immune plasma (p < 0.05).
d
Group 2 differed from the others in terms of LMWH use (p < 0.05).
e
LMWH start time was higher in group 4 than in Groups 1, 3, 5; lower in Group 1 than in 5 and 6 (p < 0.05).
f
Use of tocilizumab in Groups 5 and 7 was different from each other (p < 0.05).
g
Use of vitamin C was higher in Groups 4, 5, and 7 than others (p < 0.05).
h
Group 7 differed from Groups 1, 2, 3, 5, and 6 in terms of cytokine adsorption (p < 0.05).
- Chi-square, post hoc Bonferroni test was used for statistical analysis and the variables are presented as n (%).
- G: Group, LMWH: Low-molecular-weight heparin
a

b

18 (22.0)

4 (4.9)
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Time from symptom onset to the administration of immune plasma (days) -

30 (52.6)

Overall
(n: 321)
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Table 7. Survival by the demographic and clinical characteristics.
Current status
Dead

Total

p value

Age (years)
53.09 ± 14.11
Sex
Male
148 (78.3)
Female
107 (81.1)
Smoker (n: 274)
Yes
148 (79.1)
No
76 (87.4)
Severity of pneumonia
Mild
96 (94.1)
Moderate
83 (80.6)
Severe
76 (65.5)
Need for Intensive care unit
No
221 (99.1)
Yes
34 (34.7)
Mechanical ventilation
No
246 (96.9)
Yes
9 (13.4)
Steroid type (n: 124)
Methyl prednisolone
48 (56,.5)
Dexamethasone
26 (66.7)
Immune plasma
No
234 (89.0)
Yes
21 (36.2)
Tocilizumab (n: 320)
No
253 (83.0)
Yes
1 (6.7)
Vitamin C
No
65 (84.4)
Yes
190 (77.9)
Cytokine adsorption
No
247 (82.6)
Yes
8 (36.4)
Comorbidity

67.77 ± 10.39

56.11 ± 14.67

<0.001

41 (21.7)
25 (18.9)

189 (58.9)
132 (41.1)

0.548

39 (20.9)
11 (12.6)

187 (68.2)
87 (31.8)

0.130

6 (5.9)
20 (19.4)
40 (34.5)

102 (31.8)
103 (32.1)
116 (36.1)

<0.001

2 (0.9)
64 (65.3)

223 (69.5)
98 (30.5)

<0.001

8 (3.1)
58 (86.6)

254 (79.1)
67 (20.9)

<0.001

37 (43.5)
13 (33.3)

85 (68.5)
39 (31.5)

0.380

29 (11.0)
37 (63.8)

263 (81.9)
58 (18.1)

<0.001

52 (17.0)
14 (93.3)

305 (95.3)
15 (4.7)

<0.001

12 (15.6)
54 (22.1)

77 (24.0)
244 (76.0)

0.259

52 (17.4)
14 (63.6)

299 (93.1)
22 (6.9)

<0.001

No
Yes
Treatment group
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

136 (88.3)
119 (71.3)

18 (11.7)
48 (28.7)

154 (48.0)
167 (52.0)

<0.001

43 (97.7)
31 (100.0)
53 (72.6)
27 (81.8)
61 (74.4)
30 (73.2)
10 (58.8)

1 (2.3)
0 (0.0)
20 (27.4)
6 (18.2)
21 (25.6)
11 (26.8)
7 (41.2)

44 (13.7)
31 (9.7)
73 (22.7)
33 (10.3)
82 (25.5)
41 (12.8)
17 (5.3)

Variables

Alive

The variables are presented as mean ± SD and n (%).
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Table 8. Survival analyses by the treatment groups and main clinical characteristics.
Mean survival
(days)

STD ERR

95% CI
lower limit

95% CI
upper limit

p value

23.00

2.31

18.46

27.53

-

Male

33.61

4.49

24.79

42.42

Female

31.25

4.02

23.36

39.13

No

37.22

4.55

28.28

46.16

Yes

37.49

4.02

29.59

45.38

No

32.64

0.25

32.14

33.14

Yes

29.57

2.86

23.97

35.18

No

37.95

1.87

34.28

41.63

Yes

25.11

2.55

20.11

30.11

Mild/Moderate

34.56

3.90

26.91

42.21

Severe

31.73

4.39

23.13

40.34

No

30.36

3.07

24.33

36.39

Yes

31.90

3.49

25.04

38.75

No

30.50

2.93

24.75

36.25

Yes

38.70

6.41

26.14

51.27

No

36.18

4.97

26.43

45.93

Yes

29.47

3.51

22.59

36.36

No

31.93

3.13

25.77

38.08

Yes

31.40

3.14

25.23

37.56

Group 1

16.20

1.61

13.04

19.35

Group 2

-

-

-

-

Group 3

25.02

4.66

15.87

34.16

Group 4

38.80

5.52

27.97

49.63

Group 5

26.99

3.30

20.53

33.46

Group 6

33.32

6.32

21.09

45.53

Group 7

33.69

4.08

25.68

41.70

Overall survival
Sex

0.799

Smoker
0.231

Admission to ICU*
<0.001

Mechanical ventilation
<0.001

Severity of pneumonia
0.082

Comorbidity
0.349

DM
0.227

HT
0.151

Obesity
0.132

Main treatment group

0.186

*ICU: Intensive care unit
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Survival function
Main
treatment
groups
Group
Group
Group
Group
Group
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Figure. Cumulative survival in main treatment groups.
Table 9. Logistic regression analysis of risk factors for mortality.
Multivariate analysis
Variable

OR

95% CI

p value

Age

1.074

1.021–1.129

0.005

Mild

Ref

-

-

Moderate

2.448

0.448–13.378

0.302

Severe

3.622

0.784–16.743

0.099

Severity of pneumonia

Need for ICU

14.780

2.522–86.613

0.003

Mechanical ventilation

29.177

7.849–108.450

<0.001

Immune plasma

1.093

0.326–3.662

0.886

Cytokine adsorption

1.240

0.280–5.495

0.777

Comorbidity

0.655

0.193–2.221

0.497

*

Nagelkerke R square: 0.805, *ICU: Intensive care unit

of treatment, the severity of pneumonia at the beginning
of treatment, anticytokines, and supportive therapies in
addition to the main antiviral therapies.
Advanced age is the most critical risk factor for
mortality in COVID-19 disease [4,5]. We found that the
mean age of the patients with mortality was higher, as
67.77 ± 10.39 years.
The most common comorbidities in COVID-19 patients
are hypertension, diabetes, and coronary heart disease,
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respectively. The mechanism of action of hypertension
on the course of COVID-19 disease and mortality, in
particular, remains unclear [6]. Research by Taylor et al.
on risk factors associated with mortality revealed that
hypertension is a critical risk factor for mortality [7]. In
our study, survival was lower in those with comorbidity
than in those with none. The most common comorbidity
was hypertension, and patients with hypertension had
lower survival than those with other comorbidities.
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The severity of pneumonia is directly correlated to the
severity of the disease and mortality [8]. In our study, the
survival rate was significantly higher in patients with mild
pneumonia than those with severe pneumonia (94.1%
and 65.5%, respectively) according to the survival rates
examined by regression analysis based on the severity of
pneumonia at the time of initiation of antiviral therapy.
The severity of pneumonia was classified into two groups
as “mild + moderate” and “severe”, and it was found that
the survival rate in severe pneumonia was significantly
lower. We know that early initiation of antiviral therapy
in COVID-19 is critical in preventing poor clinical
prognosis [5,9]. In our study, the mean value of time from
the symptom onset to the main treatment was 3.57 ± 3.41
days. There was no significant difference between the
seven treatment groups regarding this period.
In this study, the overall mortality rate was 20.6% (n =
66), and the mortality rate within 14 days after diagnosis
was 7.5% (n = 24). A study analyzing the mortality in
hospitalized COVID-19 patients reported the overall
mortality rate as 25% [10].
Our study determined that admission to the intensive
care unit and the need for mechanical ventilation were
the most notable factors affecting mortality. Ninety-eight
patients (30.5%) were admitted to intensive care during
follow-up, and 67 required mechanical ventilation. The
average length of stay in intensive care was 15.38 days.
Similarly, Wu et al. reported that 29.64% of the patients
required intensive care and the average length of stay in
the intensive care unit was 18 days [5].
As for the nonantiviral treatments, we found that 124
patients (38.6%) were provided with steroid treatment
during the follow-up, and the steroid type given to
85 of these patients was methylprednisolone (68.5%).
Dexamethasone was recommended primarily in the
Infectious Diseases Society of America (IDSA) guide
updated in February 2021. However, our study found no
significant difference between steroid type and survival
[11].
Immune plasma therapy administered in intubated
patients and at a later stage in the disease course may
be harmful rather than beneficial due to the already
developed antibodies and organ damage associated with
the hyper-immune host response4 [1].
Our study found that immune plasma was administered
to 58 (18.1%) of the patients. It was noteworthy that the
survival rate was lower in patients receiving immune
plasma. This result was associated with the fact that the
immune plasma was administered as salvage therapy to
patients requiring hospitalization, a mean of 8.69 ± 4.62
days after the onset of symptoms.

Tocilizumab was administered to 15 patients (4.7%)
and cytokine adsorption to 22 patients (6.9%) diagnosed
with COVID-19–related cytokine storm. Survival rates
were lower in patients who underwent tocilizumab and
cytokine adsorption. Recent studies have reported that
tocilizumab would be more beneficial if administered
early (in the first 48 h) in patients admitted to intensive
care for rapidly progressing COVID-19 disease [12]. We
found that high-cost cytokine adsorption and tocilizumab,
which requires a specific procedure and permission for its
procurement, can only be applied to those admitted to
intensive care and do not respond to standard therapy and
steroids and have advanced stage and severe disease. We
think that this might have led to low survival rates in both
treatments.
Survival duration was significantly higher in Groups 1
and 2 compared to other groups. We think that this might
be due to several factors. First, Groups 1 and 2 had higher
rates of mild pneumonia than the others. Groups 5, 6, and
7 had the highest rate of severe pneumonia. Moreover,
we know that the disease progresses more severely at
an advanced age and in the presence of comorbidities
[5]. The mean age in Groups 1 and 2 was lower, and the
comorbidity rate was reduced compared to the other
groups. Patients in Groups 1 and 2 (HCQ-based groups)
stayed in the hospital for a shorter period in total and had
lower rates of intensive care and mechanical ventilation.
The observational study by Geleris et al. reported that the
use of HCQ did not have any significant effect on the need
for intubation or mortality [13]. Moreover, since Groups 1
and 2 had more cases of mild pneumonia, and laboratory
values for the poor prognosis (lymphocyte count, N/L
ratio, LDH level, ferritin level, d dimer level, CRP) were
better than the other groups, and the difference was
statistically significant.
Studies report that HCQ treatment has no positive
effect on clinical improvement and mortality in COVID-19
pneumonia. However, a randomized controlled study has
emphasized that when administered to patients with mild
pneumonia, a significant difference is found in clinical
improvement compared to the control group [14–16]. In
Groups 1 and 2, in which the main treatment was HCQ
and HCQ + Oseltamivir, mortality and intensive care
admission rates were lower since most patients had mild
pneumonia.
The survival rate in patients who required intensive
care was lower than those who were not (34.7% and 99.1%,
respectively). Among these patients, patients who required
mechanical ventilation had lower survival rates than those
who did not (13.4% and 96.9%, respectively). In terms of
prognostic factors affecting overall survival, univariate

T.C. Sağlık Bakanlığı COVID- 19 immün (konvalesan) plazma tedarik ve klinik kullanim rehberi 2020: 1–21 [online]. Website https://shgm.saglik.gov.
tr/Eklenti/39179/0/covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberipdf.pdf [accessed April 6, 2021].
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Cox regression analysis revealed that ICU admission
increased mortality by 11.1 times and mechanical
ventilation increased mortality by 6.48 times. The variables
found significant were included in the multivariate Cox
regression analysis. The analysis found that mechanical
ventilation increased mortality by 3.9 times. Moreover,
some studies have indicated that mechanical ventilation
has no significant effect on mortality [7].
4.1. Limitations of the study
Our study has some limitations. Firstly, the number of
patients was substantially low in the remdesivir group since
we were able to reach a limited number of remdesivir, and
use it only in patients who did not respond to treatment
and had a severe clinical picture. Secondly, we were not
able to achieve homogeneity between the groups in terms
of the number of patients and the severity of the clinical
situation. This was because some treatment protocols were
used for a short time and in a small number of patients, but
some protocols were used for a longer period of time and
a larger number of patients, and the retrospective nature
of the study.
4.2. Conclusion
The World Health Organization Solidarity study reports
that remdesivir, HCQ, lopinavir, and interferon regimens
have little or no effect on overall mortality, need for
ventilation, and length of hospital stay in COVID-19
patients [17]. Similarly, the IDSA guidelines updated in
February 2021 report that no clear positive benefit could
be obtained from any treatment option, considering the
profit and loss among the COVID-19 treatment options
[11].
The study by Ciftciler et al., in which they compiled
scientific publications on COVID-19 in Turkey in the first
year of the pandemic, reported that most studies were
about transmission, prevention, characteristics of the

disease, and diagnosis, and very few of them were clinical
trials regarding “treatment” [18]. The literature referenced
in this study and the last one-year period after this study
was searched from the Pubmed database. No other clinical
study was found in Turkey in which so many treatment
protocols were evaluated together in COVID-19 treatment.
Therefore, this study is critical in being a chronological
reflection of the different treatment options used in the
first year of the pandemic in Turkey.
In our study, which evaluated the seven main treatment
protocols, such as “HCQ”, “HCQ+oseltamivir”, “5-day
FAV”, “10-day FAV”, “HCQ followed by FAV”, “HCQ+
FAV”, and “FAV followed by remdesivir”, there was no
significant difference between the groups in terms of
the effect on survival, according to the Multivariate Cox
regression analysis.
Mutations that develop in the virus structure have
reduced the number of treatment options and vaccine
effectiveness. For this reason, the pandemic continues to
hit the world without losing its effect. This study revealed
that admission to intensive care increased mortality by
11.1 times, and mechanical ventilation increased mortality
by 6.48 times. Therefore, apart from the current treatment
options for COVID-19, it is believed that we need newer,
faster, and more effective antiviral therapies that can be
used orally in outpatient treatment without the need for
intensive care or mechanical ventilation.
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